Bayer to present new Xofigo data at ASCO GU 2016

Bayer will be attending the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2016) this week, where it will be presenting new clinical data on its drug Xofigo.

Taking place in San Francisco from January 7th to 9th, the symposium will give Bayer an opportunity to share its latest findings on the radium-223 dichloride therapy, which is approved for the treatment of prostate cancer.

The data will include the first set of safety and efficacy findings on Xofigo re-treatment from a phase II study of metastatic castration-resistant prostate cancer patients with bone metastases.

In the study, patients who had been treated with an initial course of six doses of Xofigo received up to six additional doses of the drug.

Findings from the presented studies will offer insights into the benefits of the drug, which is approved in more than 40 countries worldwide for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

It is also being studied in additional trials for men with prostate cancer, as well as in phase II studies for women with breast cancer.